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PubMed and MEDLINE search strategy
Last search performed in: 02/19/2019 #1 "chronic kidney disease"[All Fields] #2 "Chronic Kidney Disease-Mineral and Bone Disorder"[Mesh] #3 "chronic kidney failure"[All Fields] #4 "chronic renal disease"[All Fields] #5 "chronic renal failure"[All Fields] #6 "chronic renal insufficiency"[All Fields] #7 "chronic"[All Fields] AND "kidney"[All Fields] AND "disease"[All Fields] #8 "chronic"[All Fields] AND "renal"[All Fields] AND "disease"[All Fields] #9 "chronic"[All Fields] AND "renal"[All Fields] AND "failure"[All Fields] #10 "dialysis"[All Fields] #11 "dialysis" [MeSH] #12 "end stage renal disease"[All Fields] #13 "end"[All Fields] AND "stage"[All Fields] AND "renal"[All Fields] AND "disease"[All Fields] #14 "esrd"[All Fields] #15 "haemodialysis"[All Fields] #16 "hemodialysis"[All Fields] #17 "kidney failure, chronic"[MeSH] #18 "kidney"[All Fields] AND "failure"[All Fields] AND "chronic"[All Fields] #19 "renal dialysis"[Mesh] #20 "Renal Insufficiency, Chronic"[Mesh] #21 "renal"[All Fields] AND "insufficiency"[All Fields] AND "chronic"[All Fields] #22 CKD [All Fields] #23 CRF [All Fields] #24 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 #25 "mortality"[All Fields] #26 "mortality"[MeSH] #27 "mortality"[Subheading] #28 "death"[All Fields] #29 "death"[MeSH] #30 "survival"[All Fields] #31 "survival" [MeSH] #32 "survival rate"[Mesh] #33 #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 #34 "meta"[All Fields] #35 "Meta-Analysis"[Publication Type] #36 #34 OR #35 #38 #24 AND #33 AND #36
Details of data analytic methods
Assessment of heterogeneity
We performed Cochran's Q test and calculated the I2 statistic for evaluation of heterogeneity 1,2. I2 ranges from 0% to 100% and describes the percentage of variability in a study estimate that is due to between-study heterogeneity. I2 > 50% was regarded as large heterogeneity. Significant heterogeneity indicates presence of genuine heterogeneity or bias.
Estimation of the prediction interval
We estimated the 95% prediction interval, which is the range where a true effect of the intervention is to be expected for 95% of similar studies in the future 3. While the summary effects of random-effects meta-analysis represent the average effect of included studies, prediction interval estimates the treatment effect of individual studies in future settings 4. For example, a 95% prediction interval of risk ratio = (2 to 4) implies that 95% of future studies are expected to show a risk ratio between 2 and 4. Prediction intervals centers around random effects summary estimate, similar to confidence intervals. 95% prediction intervals corresponds to 95% confidence intervals when there is no in-between study heterogeneity and gets wider as in-between study heterogeneity increases. Prediction intervals including the null value suggests there may be settings where the intervention effect is null or even in the opposite direction and requires further study for identification of the causes of heterogeneity. 95% prediction interval excluding the null suggests that the treatment effect is beneficial in at least 95% of the future studies and concludes that results of treatment effects are consistent, even when some between-study heterogeneity is present.
Assessment of small study effects
We assessed small study effects, i.e. large studies having more conservative results than smaller studies, with the regression asymmetry test proposed by Egger, et al 5. Small-study effects were claimed at Egger p value < 0.1 with the effect of the largest study (the study with the smallest standard error) showing more conservative result than the summary effect of the metaanalysis under random model. Presence of small study indicates publication bias, selective reporting, or genuine heterogeneity 6.
Assessment of excess significance bias
We performed a test for excess significance to evaluate whether the number of studies reporting nominally significant results (p value < 0.05) is greater compared to the expected number of statistically significant studies 7. We assumed that the effect size of the largest study in a metaanalysis was plausible effect size of the individual studies 8. The expected probability that an individual study is statistically significant was assumed to be the power of the largest study at type I error rate = 0.05. Statistic A was calculated by the following χ2 statistic:
where O is the number of observed statistically significant studies, E is the expected number of statistically significant studies, and N is the total number of individual studies. Excess significance was claimed at p value < 0.1 with the number of observed significant studies larger than the number of expected significant studies. Presence of excess significance indicates publication bias, selective analysis, or outcome reporting bias. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
2-3
Information sources 7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.
Search 8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
2-3, supplementary material
Study selection 9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
2-3
Data collection process 10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.
3
Data items 11
List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.
3
Risk of bias in individual studies 12
Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.
3-4
Summary measures 13 State the principal summary measures (e.g., risk ratio, difference in means).
Synthesis of results 14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I 2 ) for each meta-analysis.
3-4, supplementary material
Section/topic # Checklist item Reported on page #
Risk of bias across studies 15
Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).
3-4
Additional analyses 16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.
RESULTS
Study selection
17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. Study characteristics 18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.
4,7-12
Risk of bias within studies 19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12). 7-8, Table 2 , Table S2-S6 Results of individual studies 20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. 7-8, Table 2 , Table S2 -S6
Synthesis of results 21 Present results of each meta-analysis done, including confidence intervals and measures of consistency. 7-8, Table 2 , Table S2 -S5
Risk of bias across studies 22 Present results of any assessment of risk of bias across studies (see Item 15). 7-8, Table 2 , Table S2 -S5 Additional analysis 23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16] ).
N/A
DISCUSSION
Summary of evidence 24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).
15-16
Limitations 25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).
16-17
Conclusions 26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.
17
FUNDING Funding 27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. None * Represented as median or range of follow-up duration of individual studies. † Summary estimate smaller than 1 favors experimental arm (lower mortality in experimental arm); effect estimate larger than 1 favors control arm (lower mortality in control arm) ‡ Any of the following: large heterogeneity, signs of small study effects, signs of excess significance bias, or loss of statistical significance in 10% credibility ceiling. All statistical tests are two-sided. Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMS, bare metal stent; CABG, coronary artery bypass; CI, confidence interval; CKD, chronic kidney disease; DES, drug-eluting stent; HD, hemodialysis; HR, hazard ratio; ICD, implantable cardioverter defibrillator; NA, not available; NR, not reported; OR, odds ratio; PCI, percutaneous intervention; PD, peritoneal dialysis; PKD, polycystic kidney disease; RAAS, renin-angiotensinaldosterone system; RR, risk ratio; vs., versus Random effect summary estimate was not significant * Effect estimate smaller than 1 favors experimental arm (lower mortality in experimental arm); effect estimate larger than 1 favors control arm (lower mortality in control arm) All statistical tests are two-sided. Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMS, bare metal stent; CI, confidence interval; CKD, chronic kidney disease; DES, drug-eluting stent; DPP-4, Dipeptidylpeptidase-4; ESA, erythropoiesis-stimulating agent; HD, hemodialysis; HR, hazard ratio; ICD, implantable cardioverter defibrillator; NA, not available; OR, odds ratio; PD, peritoneal dialysis; RR, risk ratio; SGLT-2, sodium glucose cotransporter-2; vs., versus All statistical tests are two-sided. Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; acm, all-cause mortality; ARB, angiotensin receptor blocker; BMS, bare metal stent; CABG, coronary artery bypass; CI, confidence interval; CKD, chronic kidney disease; DES, drugeluting stent; HR, hazard ratio; ICD, implantable cardioverter defibrillator; NR, not reported; OR, odds ratio; OS, observational study; PCI, percutaneous intervention; RCT, randomized controlled trial; RR, risk ratio; vs., versus Highly suggestive to weak a. Summary estimate smaller than 1 favors experimental arm (lower mortality in experimental arm); effect estimate larger than 1 favors control arm (lower mortality in control arm) b. Any of the following: large heterogeneity, signs of small study effects, signs of excess significance bias, and for observational studies, loss of statistical significance in 10% credibility ceiling. All statistical tests are two-sided. Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CABG, coronary artery bypass grafting; CI, confidence interval; CKD, chronic kidney disease; HD, hemodialysis; HR, hazard ratio; NR, not reported; OR, odds ratio; PCI, percutaneous intervention; RR, risk ratio; vs., versus
